title: Male breast cancer. A report of 71 cases.
abstract: Male breast cancer is rare; it constitutes 0.2-1.5% of all malignant tumours in men and 1% of all breast cancers. The goal of this retrospective study is to analyse the epidemiologic, clinic, therapeutic and evolutive profiles of this disease in 71 cases collected at the National Institute of Oncology in Rabat, Morocco, between the years 1985 and 1998. The median age was 60 years. No significant risk factor was found. The average consultation's delay was 35 months. The main clinical complaint was a mass beneath the areola in 86% of the cases, associated with ulceration in 18% of the cases. For that, the disease was diagnosed at an advanced stage. Infiltrating ductal carcinoma was the most frequent pathologic type (91.5% of cases). Management consisted especially of radical mastectomy, followed by adjuvant radiotherapy and hormonal therapy with or without chemotherapy. It was possible to follow 58 of the patients. The median of follow-up was 30 months. The evolution has been characterized by local recurrence, after a median delay of 36 months, in five cases (8.5% of all patients). Metastasis occurred, after a median delay of 12 months, in 14 cases (24% of all patients). The site of metastasis was the bone in six cases, lung in five cases, liver in one case, liver and skin in one case and pleura and skin in one case. There were three cases of death. In one case, death was related to lung metastases. In the two remaining cases, death was due to comorbid disease. Progression was observed in one case.
authors.affiliation: National institute of oncology, Rabat, Morocco. omari_alaoui@yahoo.fr
authors.forename: H
authors.initials: H
authors.lastname: El Omari-Alaoui
authors.forename: I
authors.initials: I
authors.lastname: Lahdiri
authors.forename: I
authors.initials: I
authors.lastname: Nejjar
authors.forename: K
authors.initials: K
authors.lastname: Hadadi
authors.forename: F
authors.initials: F
authors.lastname: Ahyoud
authors.forename: H
authors.initials: H
authors.lastname: Hachi
authors.forename: M
authors.initials: M
authors.lastname: Alhilal
authors.forename: H
authors.initials: H
authors.lastname: Errihani
authors.forename: N
authors.initials: N
authors.lastname: Benjaafar
authors.forename: A
authors.initials: A
authors.lastname: Souadka
authors.forename: B K
authors.initials: BK
authors.lastname: El Gueddari
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D018567:Breast Neoplasms, Male / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D015994:Incidence; D008297:Male; D015409:Mastectomy, Radical; D008875:Middle Aged; D009018:Morocco / Q000453:epidemiology; D009362:Neoplasm Metastasis; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies
chemical_list: D018931:Antineoplastic Agents, Hormonal